A vitamin D-based strategy overcomes chemoresistance in prostate cancer.
Fiche publication
Date publication
juillet 2024
Journal
British journal of pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MASSFELDER Thierry, Dr METZGER Daniel, Dr ROCHEL-GUIBERTEAU Natacha, Dr LAVERNY Gilles
Tous les auteurs :
Len-Tayon K, Beraud C, Fauveau C, Belorusova AY, Chebaro Y, Mouriño A, Massfelder T, Chauchereau A, Metzger D, Rochel N, Laverny G
Lien Pubmed
Résumé
Castration-resistant prostate cancer (CRPC) is a common male malignancy that requires new therapeutic strategies due to acquired resistance to its first-line treatment, docetaxel. The benefits of vitamin D on prostate cancer (PCa) progression have been previously reported. This study aimed to investigate the effects of vitamin D on chemoresistance in CRPC.
Mots clés
castration resistant prostate cancer, docetaxel resistance, patient‐derived xenografts, spheroids, vitamin D analogues
Référence
Br J Pharmacol. 2024 07 9;: